NEW YORK--(BUSINESS WIRE)--Today, Demy-Colton rolled out a provocative agenda for its industry-transforming BioFuture™ 2024 conference, set to take place at Cure, New York City’s leading health innovation hub, October 28-30, 2024. A virtual component will follow from November 5-7, 2024, offering global attendees access to recorded sessions and virtual one-on-one meetings.
The dynamic program features biotech, techbio, healthcare delivery and technology industry experts and thought leaders on policy, the influence of technology on innovation, and the financial landscape for 2025. This year’s lineup includes influential speakers from Regeneron, Moderna, Johnson & Johnson, Endpoints News, Northwell Health, IBM, Ipsen, JP Morgan and Pappas Capital among many others. Session highlights include:
- Tackling the Hard Questions: Policy, PBMs, The IRA featuring Jennifer Hawks Bland, CEO, NewYorkBIO; Congressman Jake Auchincloss, D, MA-04; Nouhad Husseini, SVP, Head of Business Development & Corporate Strategy, Regeneron Pharmaceuticals; Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer, Ipsen; Neal Masia, Co-Founder & CEO, EntityRisk; and Peter Rubin, Executive Director, No Patient Left Behind.
- The Financial Landscape: Are We Coming Out of the Fog? featuring Stephen Thau, Partner, Co-Head of Life Sciences Practice, Orrick; Tim Opler, Managing Director, Global Healthcare Group, Stifel; Art Pappas, CEO & Managing General Partner, Pappas Capital; Dennis Purcell, Founder, Aisling Capital; and Evonne Sepsis, Founder & Managing Director, ESC Advisors.
- Quantum Computing and Biology: The Convergence Reshaping the Future of Human Health featuring Querida Anderson, Senior Editor, Healthcare; McKinsey Global Publishing, Wade Davis, VP, Computational Science & Head, Digital Research and Alexey Galda, Associate Scientific Director, Quantum Algorithms & Applications, Moderna; and Victoria Lipinska, Americas Lead for Quantum Innovation Centers, IBM
“BioFuture has earned a reputation both for unmatched networking opportunities and for leaning into the tough discussions that help executives navigate emerging challenges and opportunities,” said Sara Jane Demy, Founder & CEO of Demy-Colton. “We’ve carefully curated this year’s agenda to reflect the rapid evolution of the healthcare ecosystem, and we’re excited to host more than 100 investors, 40 media representatives and 80 public and private companies in dialog about the issues impacting the biotech, pharma, techbio and digital health sectors.”
Demy-Colton encourages innovative public and private biotech, techbio, digital medicine and AI/ML companies to register to attend or apply to present. Qualified investors and media are encouraged to apply for complimentary registration. For more information about registering for the event, presenting opportunities, or sponsorships, visit www.biofuture.com and follow #BioFuture2024 on X.
About Demy-Colton
Demy-Colton is a premier life sciences events organization committed to connecting industry leaders and fostering partnerships that advance life sciences innovation globally. Demy-Colton’s portfolio includes Biotech Showcase™, BioFuture™, and the Biotech CEO Summits in Europe and La Jolla, as well as virtual events designed to keep life sciences professionals connected year-round.
